Cancer vaccines edge toward breakthrough, but misinformation could slow adoption

An mRNA cancer vaccine has achieved a late-stage success—Moderna and Merck's personalized vaccine intismeran autogene reduced melanoma recurrence when paired with Keytruda—pointing to a new frontier in cancer treatment and prevention, but persistent misinformation about mRNA technology, including the 'turbo cancer' narrative, threatens to erode public trust and slow adoption; experts say proactive, transparent communication, clinician training, and public health messaging are essential to translate scientific progress into real-world benefits.